Publicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (12)

2022

  1. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update)

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 14, Núm. 1, pp. 5-12

2020

  1. Is vitamin-D supplementation not useful in patients at risk of fractures and falls?

    Gynecological Endocrinology, Vol. 36, Núm. 2, pp. 93-95

2017

  1. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

2016

  1. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks

    Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878

2014

  1. Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 4, pp. 250-258

2011

  1. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis

    Bone, Vol. 48, Núm. 5, pp. 972-978

2010

  1. Back pain during different sequential treatment regimens of teriparatide: Results from EUROFORS

    Current Medical Research and Opinion, Vol. 26, Núm. 8, pp. 1799-1807

  2. The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density

    Osteoporosis International

2009

  1. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

    Journal of Bone and Mineral Research

  2. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled european study of forsteo (EUROFORS)

    Journal of Bone and Mineral Research, Vol. 24, Núm. 4, pp. 726-736

2008

  1. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

    Journal of Bone and Mineral Research, Vol. 23, Núm. 10, pp. 1591-1600

2007

  1. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study

    Journal of Bone and Mineral Research, Vol. 22, Núm. 9, pp. 1426-1433